Table 1Pharmacological and Nonpharmacological Interventions Studied in the Review

Non-SSRI Antidepressants
Augmenting and Nonantidepressant Agents
  • Anticonvulsants
  • Antiprogestational agents
  • Dopamine agonists
  • Psychostimulants
  • Sex hormones
  • Thyroid medications
  • Other drugs such as buspirone (Buspar®), lithium, pindolol, and tryptophan
Atypical Antipsychotics**:
Nonpharmacological Therapies
  • Cognitive behavioral therapy
  • Exercise
  • Interpersonal therapy
  • Other psychotherapies

Concomitant use of selective serotonin-reuptake inhibitors (SSRIs) in patients taking monoamine oxidase inhibitors (MAOIs; e.g., phenelzine [Nardil®], selegiline transdermal system [EMSAM®], tranylcypromine [Parnate®]) is contraindicated, as cases of serious and sometimes fatal reactions have been reported. These reactions have also been reported in patients who have recently discontinued an SSRI or other drugs that interfere with serotonin metabolism and have been started on an MAOI. For additional information, see the U.S. Food and Drug Administration (FDA) safety announcements at www‚Äč


Aripiprazole (Abilify®) and quetiapine XR (Seroquel XR®) have been approved by the FDA to be added to an antidepressant to treat adults with major depressive disorder. Olanzapine (Zyprexa®) has been approved by the FDA to be added to the SSRI fluoxetine (Prozac®, Prozac Weekly®, Sarafem®) to treat adults with treatment-resistant depression.

From: Treatment for Depression After Unsatisfactory Response to SSRIs in Adults and Adolescents

Cover of Comparative Effectiveness Review Summary Guides for Clinicians
Comparative Effectiveness Review Summary Guides for Clinicians [Internet].

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.